Koers Oncolytics Biotech Inc. Toronto S.E.
Aandelen
CA6823101077
Biotechnologie & Medisch Onderzoek
Omzet 2024 * | 1 mln. 734K 677K | Omzet 2025 * | 8,12 mln. 5,96 mln. 5,5 mln. | Marktkapitalisatie | 117 mln. 85,77 mln. 79,11 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -34 mln. -24,95 mln. -23,01 mln. | Nettowinst (verlies) 2025 * | -39 mln. -28,61 mln. -26,39 mln. | EV/omzet 2024 * | 117 x |
Nettoliquiditeiten 2024 * | - 0 0 | Nettoliquiditeiten 2025 * | - 0 0 | EV/omzet 2025 * | 14,4 x |
K/w-verhouding 2024 * |
-3,8
x | K/w-verhouding 2025 * |
-4,22
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 96,1% |
Recentste transcriptie over Oncolytics Biotech Inc.
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Matthew Coffey
CEO | Chief Executive Officer | - | 11-05-11 |
Kirk Look
DFI | Director of Finance/CFO | - | 01-04-03 |
Thomas Heineman
CTO | Chief Tech/Sci/R&D Officer | - | 01-08-20 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Jonathan Rigby
BRD | Director/Board Member | 56 | 07-09-22 |
Patricia Andrews
BRD | Director/Board Member | 66 | 09/01 |
Bernd Seizinger
BRD | Director/Board Member | 67 | 08-06-15 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+33,37% | 50,85 mld. | |
+1,55% | 42,82 mld. | |
+49,17% | 42,03 mld. | |
-4,22% | 29,55 mld. | |
+11,57% | 26,11 mld. | |
-21,00% | 19,13 mld. | |
+7,36% | 13,05 mld. | |
+28,30% | 12,16 mld. | |
+23,80% | 12,08 mld. |